Rubius Therapeutics Inc (NASDAQ:RUBY) insider Christopher L. Carpenter sold 48,000 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $15.84, for a total transaction of $760,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
RUBY stock opened at $16.52 on Thursday. Rubius Therapeutics Inc has a 12 month low of $12.70 and a 12 month high of $33.01. The company has a debt-to-equity ratio of 0.06, a quick ratio of 25.78 and a current ratio of 25.78.
Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Rubius Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Wednesday, January 16th. ValuEngine downgraded shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Morgan Stanley reduced their price target on shares of Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, December 19th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $30.00.
A number of hedge funds have recently added to or reduced their stakes in RUBY. Legal & General Group Plc acquired a new position in Rubius Therapeutics in the 3rd quarter valued at $44,000. New York State Common Retirement Fund acquired a new position in Rubius Therapeutics in the 4th quarter valued at $116,000. Metropolitan Life Insurance Co. NY increased its stake in Rubius Therapeutics by 320.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock valued at $116,000 after buying an additional 5,481 shares during the period. LPL Financial LLC acquired a new position in Rubius Therapeutics in the 4th quarter valued at $162,000. Finally, Bank of America Corp DE increased its stake in Rubius Therapeutics by 601.5% in the 4th quarter. Bank of America Corp DE now owns 11,048 shares of the company’s stock valued at $178,000 after buying an additional 9,473 shares during the period. Hedge funds and other institutional investors own 87.04% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by Zolmax and is the sole property of of Zolmax. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://zolmax.com/investing/christopher-l-carpenter-sells-48000-shares-of-rubius-therapeutics-inc-ruby-stock/2978742.html.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Read More: Are all No-Load Funds Equal?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.